DK1963307T3 - 3-(4-{[4-(4-{[3-(3,3-dimethyl-1-piperidinyl)propyl]oxy}phenyl)-1-piperidinyl]carbonyl}-1-naphthalenyl)propion- eller propensyre som H1- og H3-receptorantagonister til behandling af inflammatoriske og/eller allergiske lidelser - Google Patents
3-(4-{[4-(4-{[3-(3,3-dimethyl-1-piperidinyl)propyl]oxy}phenyl)-1-piperidinyl]carbonyl}-1-naphthalenyl)propion- eller propensyre som H1- og H3-receptorantagonister til behandling af inflammatoriske og/eller allergiske lidelserInfo
- Publication number
- DK1963307T3 DK1963307T3 DK06841477.0T DK06841477T DK1963307T3 DK 1963307 T3 DK1963307 T3 DK 1963307T3 DK 06841477 T DK06841477 T DK 06841477T DK 1963307 T3 DK1963307 T3 DK 1963307T3
- Authority
- DK
- Denmark
- Prior art keywords
- piperidinyl
- naphthalenyl
- oxy
- propionic
- carbonyl
- Prior art date
Links
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 title 2
- -1 4 - {[4- (4 - {[3- (3,3-Dimethyl-1-piperidinyl) propyl] oxy} phenyl) -1-piperidinyl] carbonyl} -1-naphthalenyl Chemical group 0.000 title 1
- 102000003834 Histamine H1 Receptors Human genes 0.000 title 1
- 108090000110 Histamine H1 Receptors Proteins 0.000 title 1
- 102000004384 Histamine H3 receptors Human genes 0.000 title 1
- 108090000981 Histamine H3 receptors Proteins 0.000 title 1
- 230000000172 allergic effect Effects 0.000 title 1
- 208000010668 atopic eczema Diseases 0.000 title 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000002757 inflammatory effect Effects 0.000 title 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 title 1
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Otolaryngology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0525897A GB0525897D0 (en) | 2005-12-20 | 2005-12-20 | Compounds |
| GB0623217A GB0623217D0 (en) | 2006-11-21 | 2006-11-21 | Compounds |
| PCT/EP2006/069943 WO2007071691A1 (en) | 2005-12-20 | 2006-12-19 | 3- (4-{ [4-(4-{ [3-(3, 3-dimethyl-1-piperidinyl) propyl] 0xy} phenyl) -1-piperidinyl] carbonyl }-1-naphthalenyl) propanoic or propenoic acid as h1 and h3 receptor antagonists for the treatment of inflammatory and/or allergic disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1963307T3 true DK1963307T3 (da) | 2010-04-06 |
Family
ID=37845266
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK06841477.0T DK1963307T3 (da) | 2005-12-20 | 2006-12-19 | 3-(4-{[4-(4-{[3-(3,3-dimethyl-1-piperidinyl)propyl]oxy}phenyl)-1-piperidinyl]carbonyl}-1-naphthalenyl)propion- eller propensyre som H1- og H3-receptorantagonister til behandling af inflammatoriske og/eller allergiske lidelser |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US7989629B2 (da) |
| EP (2) | EP2157087A1 (da) |
| JP (2) | JP4445570B2 (da) |
| KR (1) | KR20080087102A (da) |
| AR (1) | AR058109A1 (da) |
| AT (1) | ATE449769T1 (da) |
| AU (1) | AU2006328512B2 (da) |
| BR (1) | BRPI0620218A2 (da) |
| CA (1) | CA2634391A1 (da) |
| CR (1) | CR10102A (da) |
| CY (1) | CY1110601T1 (da) |
| DE (1) | DE602006010737D1 (da) |
| DK (1) | DK1963307T3 (da) |
| EA (1) | EA014354B1 (da) |
| ES (1) | ES2337187T3 (da) |
| IL (1) | IL191967A0 (da) |
| MA (1) | MA30373B1 (da) |
| NO (1) | NO20082695L (da) |
| PE (1) | PE20071068A1 (da) |
| PL (1) | PL1963307T3 (da) |
| PT (1) | PT1963307E (da) |
| SI (1) | SI1963307T1 (da) |
| TW (1) | TW200730498A (da) |
| WO (1) | WO2007071691A1 (da) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2010012814A (es) | 2008-05-23 | 2010-12-20 | Amira Pharmaceuticals Inc | Inhibidor de proteina activadora de 5-lipoxigenasa. |
| WO2011000765A1 (en) | 2009-06-29 | 2011-01-06 | Glaxo Group Limited | New medical use |
| JP4785963B2 (ja) | 2009-10-09 | 2011-10-05 | キヤノン株式会社 | 固体撮像装置 |
| WO2013151982A1 (en) | 2012-04-03 | 2013-10-10 | Arena Pharmaceuticals, Inc. | Methods and compounds useful in treating pruritus, and methods for identifying such compounds |
| US20170100385A1 (en) | 2014-05-12 | 2017-04-13 | Glaxosmithkline Intellectual Property (No. 2) Limited | Pharmaceutical compositions comprising danirixin for treating infectious diseases |
| KR101640756B1 (ko) | 2014-10-28 | 2016-07-19 | 이종찬 | 전동 드릴 장착용 내시경 캡 |
| EP3758689A4 (en) * | 2018-03-01 | 2022-01-12 | Ferox Therapeutics LLC | METHODS FOR THE PREVENTION AND TREATMENT OF HYPOGLYCEMIA IN PATIENTS WITH TYPE 1 AND TYPE 2 DIABETES |
| WO2021191875A1 (en) | 2020-03-26 | 2021-09-30 | Glaxosmithkline Intellectual Property Development Limited | Cathepsin inhibitors for preventing or treating viral infections |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9127376D0 (en) | 1991-12-24 | 1992-02-19 | Wellcome Found | Amidino derivatives |
| US5552438A (en) | 1992-04-02 | 1996-09-03 | Smithkline Beecham Corporation | Compounds useful for treating allergic and inflammatory diseases |
| EP0745121B1 (en) | 1992-05-14 | 2007-06-20 | Baylor College Of Medicine | Mutated steroid hormone receptors, methods for their use and molecular switch for gene therapy |
| US5364791A (en) | 1992-05-14 | 1994-11-15 | Elisabetta Vegeto | Progesterone receptor having C. terminal hormone binding domain truncations |
| DE69529101T2 (de) | 1994-06-15 | 2003-11-13 | Wellcome Found | Zwischenprodukte verwendbar in der Herstellung von Enzym-Inhibitoren |
| MY117948A (en) | 1997-01-13 | 2004-08-30 | Glaxo Group Ltd | Nitride oxide synthase inhibitors. |
| DE19723722A1 (de) | 1997-05-30 | 1998-12-10 | Schering Ag | Nichtsteroidale Gestagene |
| WO1999016766A1 (en) | 1997-10-01 | 1999-04-08 | Kyowa Hakko Kogyo Co., Ltd. | Benzodioxole derivatives |
| US6506766B1 (en) | 1998-02-13 | 2003-01-14 | Abbott Laboratories | Glucocortiocoid-selective antinflammatory agents |
| SI1070056T1 (en) | 1998-03-14 | 2004-12-31 | Altana Pharma Ag | Phthalazinone pde iii/iv inhibitors |
| GB9811599D0 (en) | 1998-05-30 | 1998-07-29 | Glaxo Group Ltd | Nitric oxide synthase inhibitors |
| WO2000066590A2 (en) | 1999-05-04 | 2000-11-09 | Ligand Pharmaceuticals, Inc. | Tetracyclic progesterone receptor modulator compounds and methods |
| ES2165768B1 (es) | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
| CO5180649A1 (es) | 1999-09-01 | 2002-07-30 | Abbott Lab | Antagonistas de los receptores de los glucocorticoides para el tratamiento de la diabetes para el tratamiento de la diabetes |
| OA11558A (en) | 1999-12-08 | 2004-06-03 | Advanced Medicine Inc | Beta 2-adrenergic receptor agonists. |
| SI1775305T1 (sl) | 2000-08-05 | 2015-01-30 | Glaxo Group Limited | S-fluorometil ester 6alfa,9alfa-difluoro-17alfa-((2-furanilkarboksil)oksi)- 11beta-hidroksi-16alfa-metil-3-okso-androst-1,4-dien-17-karbotiojske kisline kot protivnetno sredstvo |
| GB0031179D0 (en) | 2000-12-21 | 2001-01-31 | Glaxo Group Ltd | Nitric oxide synthase inhibitors |
| US6484903B2 (en) | 2001-01-09 | 2002-11-26 | Riverwood International Corporation | Carton with an improved dispensing feature in combination with a unique handle |
| GB0103630D0 (en) | 2001-02-14 | 2001-03-28 | Glaxo Group Ltd | Chemical compounds |
| US7144908B2 (en) | 2001-03-08 | 2006-12-05 | Glaxo Group Limited | Agonists of beta-adrenoceptors |
| ES2296923T3 (es) | 2001-03-22 | 2008-05-01 | Glaxo Group Limited | Derivados formanilidas como agonistas del adrenorreceptor beta2. |
| KR20090057477A (ko) | 2001-09-14 | 2009-06-05 | 글락소 그룹 리미티드 | 호흡기 질환 치료용 펜에탄올아민 유도체 |
| US6653323B2 (en) | 2001-11-13 | 2003-11-25 | Theravance, Inc. | Aryl aniline β2 adrenergic receptor agonists |
| AU2003202216A1 (en) | 2002-01-14 | 2003-07-30 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical formulations containing them and uses thereof |
| CA2473886C (en) | 2002-01-22 | 2012-08-21 | The Regents Of The University Of California | Non-steroidal ligands for the glucocorticoid receptor, compositions and uses thereof |
| GB0204719D0 (en) | 2002-02-28 | 2002-04-17 | Glaxo Group Ltd | Medicinal compounds |
| CA2478156C (en) | 2002-03-26 | 2011-02-15 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| WO2003082787A1 (en) | 2002-03-26 | 2003-10-09 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| DE10215316C1 (de) | 2002-04-02 | 2003-12-18 | Schering Ag | Chinolin- und Isochinolin-Derivate, ein pharmazeutisches Mittel und ihre Verwendung als Entzündungshemmer |
| EP1496892B1 (en) | 2002-04-11 | 2011-01-26 | Merck Sharp & Dohme Corp. | 1h-benzo(f)indazol-5-yl derivatives as selective glucocorticoid receptor modulators |
| JP2005523920A (ja) | 2002-04-25 | 2005-08-11 | グラクソ グループ リミテッド | フェネタノールアミン誘導体 |
| US7186864B2 (en) | 2002-05-29 | 2007-03-06 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| US7074806B2 (en) | 2002-06-06 | 2006-07-11 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| JP4503436B2 (ja) | 2002-07-08 | 2010-07-14 | ファイザー・プロダクツ・インク | 糖質コルチコイド受容体のモジュレーター |
| EP1534273A4 (en) | 2002-07-18 | 2007-08-22 | Bristol Myers Squibb Co | MODULATORS OF THE GLUCOCORTICOID RECEPTOR AND METHOD |
| GB0217225D0 (en) | 2002-07-25 | 2002-09-04 | Glaxo Group Ltd | Medicinal compounds |
| JP2006504678A (ja) | 2002-08-21 | 2006-02-09 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | グルココルチコイドミメチックス、その製造方法、その医薬組成物、及び使用 |
| GB0220730D0 (en) | 2002-09-06 | 2002-10-16 | Glaxo Group Ltd | Medicinal compounds |
| JP2006503108A (ja) | 2002-09-16 | 2006-01-26 | グラクソ グループ リミテッド | ピラゾロ［３，４−ｂ］ピリジン化合物およびそれのホスホジエステラーゼ阻害薬としての使用 |
| GB0230045D0 (en) | 2002-12-23 | 2003-01-29 | Glaxo Group Ltd | Compounds |
| AU2003270783C1 (en) | 2002-09-20 | 2010-05-20 | Merck Sharp & Dohme Corp. | Octahydro-2-H-naphtho[1,2-F] indole-4-carboxamide derivatives as selective glucocorticoid receptor modulators |
| GB0224084D0 (en) * | 2002-10-16 | 2002-11-27 | Glaxo Group Ltd | Novel compounds |
| EP1554264B1 (en) | 2002-10-22 | 2007-08-08 | Glaxo Group Limited | Medicinal arylethanolamine compounds |
| WO2004037800A1 (en) * | 2002-10-22 | 2004-05-06 | Glaxo Group Limited | Aryloxyalkylamine derivates as h3 receptor ligands |
| EP1556342B1 (en) | 2002-10-28 | 2008-03-26 | Glaxo Group Limited | Phenethanolamine derivative for the treatment of respiratory diseases |
| GB0225030D0 (en) | 2002-10-28 | 2002-12-04 | Glaxo Group Ltd | Medicinal compounds |
| GB0225535D0 (en) | 2002-11-01 | 2002-12-11 | Glaxo Group Ltd | Medicinal compounds |
| GB0225540D0 (en) | 2002-11-01 | 2002-12-11 | Glaxo Group Ltd | Medicinal compounds |
| GB0308333D0 (en) * | 2003-04-10 | 2003-05-14 | Glaxo Group Ltd | Novel compounds |
| TWI328009B (en) | 2003-05-21 | 2010-08-01 | Glaxo Group Ltd | Quinoline derivatives as phosphodiesterase inhibitors |
| PE20060272A1 (es) | 2004-05-24 | 2006-05-22 | Glaxo Group Ltd | (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a |
| WO2006000401A1 (en) | 2004-06-28 | 2006-01-05 | Glaxo Group Limited | Substituted oxazines as glucocorticoid receptor modulators |
| WO2006000398A1 (en) | 2004-06-28 | 2006-01-05 | Glaxo Group Limited | 2,3-benzoxazin derivatives as non-steroidal glucocorticoid receptor modulators |
| GB0418045D0 (en) | 2004-08-12 | 2004-09-15 | Glaxo Group Ltd | Compounds |
| US7465795B2 (en) | 2005-12-20 | 2008-12-16 | Astrazeneca Ab | Compounds and uses thereof |
| US20080039444A1 (en) | 2006-04-20 | 2008-02-14 | Glaxo Group Limited | Compounds |
-
2006
- 2006-12-18 PE PE2006001620A patent/PE20071068A1/es not_active Application Discontinuation
- 2006-12-18 TW TW095147457A patent/TW200730498A/zh unknown
- 2006-12-18 AR ARP060105590A patent/AR058109A1/es not_active Application Discontinuation
- 2006-12-19 ES ES06841477T patent/ES2337187T3/es active Active
- 2006-12-19 AT AT06841477T patent/ATE449769T1/de active
- 2006-12-19 KR KR1020087015535A patent/KR20080087102A/ko not_active Ceased
- 2006-12-19 PT PT06841477T patent/PT1963307E/pt unknown
- 2006-12-19 DK DK06841477.0T patent/DK1963307T3/da active
- 2006-12-19 PL PL06841477T patent/PL1963307T3/pl unknown
- 2006-12-19 JP JP2008546432A patent/JP4445570B2/ja not_active Expired - Fee Related
- 2006-12-19 US US12/158,185 patent/US7989629B2/en not_active Expired - Fee Related
- 2006-12-19 CA CA002634391A patent/CA2634391A1/en not_active Abandoned
- 2006-12-19 SI SI200630560T patent/SI1963307T1/sl unknown
- 2006-12-19 WO PCT/EP2006/069943 patent/WO2007071691A1/en not_active Ceased
- 2006-12-19 EP EP09176715A patent/EP2157087A1/en not_active Withdrawn
- 2006-12-19 AU AU2006328512A patent/AU2006328512B2/en not_active Ceased
- 2006-12-19 EA EA200801342A patent/EA014354B1/ru not_active IP Right Cessation
- 2006-12-19 EP EP06841477A patent/EP1963307B1/en active Active
- 2006-12-19 BR BRPI0620218-7A patent/BRPI0620218A2/pt not_active IP Right Cessation
- 2006-12-19 DE DE602006010737T patent/DE602006010737D1/de active Active
-
2008
- 2008-06-05 IL IL191967A patent/IL191967A0/en unknown
- 2008-06-11 MA MA31023A patent/MA30373B1/fr unknown
- 2008-06-11 NO NO20082695A patent/NO20082695L/no not_active Application Discontinuation
- 2008-06-20 CR CR10102A patent/CR10102A/es not_active Application Discontinuation
-
2009
- 2009-06-12 JP JP2009140796A patent/JP2009235087A/ja active Pending
-
2010
- 2010-02-19 CY CY20101100170T patent/CY1110601T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ATE449769T1 (de) | 2009-12-15 |
| SI1963307T1 (sl) | 2010-03-31 |
| JP4445570B2 (ja) | 2010-04-07 |
| EP1963307B1 (en) | 2009-11-25 |
| CR10102A (es) | 2008-09-22 |
| EA014354B1 (ru) | 2010-10-29 |
| AR058109A1 (es) | 2008-01-23 |
| IL191967A0 (en) | 2008-12-29 |
| KR20080087102A (ko) | 2008-09-30 |
| EP2157087A1 (en) | 2010-02-24 |
| EP1963307A1 (en) | 2008-09-03 |
| AU2006328512A1 (en) | 2007-06-28 |
| MA30373B1 (fr) | 2009-05-04 |
| DE602006010737D1 (de) | 2010-01-07 |
| PL1963307T3 (pl) | 2010-05-31 |
| AU2006328512B2 (en) | 2011-06-23 |
| TW200730498A (en) | 2007-08-16 |
| CA2634391A1 (en) | 2007-06-28 |
| PE20071068A1 (es) | 2007-12-13 |
| CY1110601T1 (el) | 2015-04-29 |
| JP2009520001A (ja) | 2009-05-21 |
| BRPI0620218A2 (pt) | 2011-11-01 |
| NO20082695L (no) | 2008-09-16 |
| US20080312280A1 (en) | 2008-12-18 |
| JP2009235087A (ja) | 2009-10-15 |
| US7989629B2 (en) | 2011-08-02 |
| PT1963307E (pt) | 2010-03-03 |
| WO2007071691A1 (en) | 2007-06-28 |
| ES2337187T3 (es) | 2010-04-21 |
| EA200801342A1 (ru) | 2008-12-30 |
| HK1120265A1 (en) | 2009-03-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LTPA2020525I1 (lt) | Kietos 3-(6-(1-(2,2-difluorbenzo[d][1,3]dioksol-5-il)ciklopropankarboksamido)-3-metilpiridin-2-il)benzoinės rūgšties formos | |
| ZA200702392B (en) | New pharmaceutical compositions comprising 4-(4-(3-(4-chloro-3-trifluoromethyl-phenyl)-ureido)-3-fluoro-phenoxy)-pyridine-2-carbo xylic acid for the treatment of hyper-proliferative disorders | |
| ATE516272T1 (de) | 1,3-disubstituierte 4-(aryl-x-phenyl)-1h-pyridin- 2-one | |
| IL191967A0 (en) | 3-(4-{[4-(4-{[3-(3,3-dimethyl-1-piperidinyl) propyl]oxy}phenyl)-1-piperidinyl]carbonyl]-1-naphthalenyl)propanoic or propenoic acid as h1 and h3 receptor antagonists for the treatment of inflammatory and/or allergic disorders | |
| DK3456707T3 (da) | 4-(p-quinonyl)-2-hydroxybutanamidderivater til behandling af mitokondriesygdomme | |
| CY2016017I1 (el) | Συνθεση για θεραπεια πνευμονικης υπερτασης | |
| ATE550329T1 (de) | Heterobicyclische sulfonamidderivate zur behandlung von diabetes | |
| DE602006010243D1 (de) | 4-(Phenylamino)-6-oxo-1,6-dihydropyridazine-3-carboxamid Derivate als MEK Inhibitoren zur Behandlung von hyperproliferativen Erkrankungen | |
| DK1968949T3 (da) | Forbedret fremgangsmåde til fremstilling af salte af 4-(benzimidazolylmethylamino)-benzamider | |
| DE602007010303D1 (de) | Verwendung von 3- (4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidin--2,6-dion zur behandlung von mantelzelllymphomen | |
| DK1907373T3 (da) | Fremgangsmåder til fremstillingen af 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindolin-1,3-dionforbindelser | |
| IL192241A0 (en) | Improved process for the preparation of 4-(benzimidazolylmethylamino)-benzamides and the salts thereof | |
| DK1812110T3 (da) | Apparat til behandling af dermatologiske lidelser | |
| DK2019683T4 (da) | Indgivelse af vækstfaktorer til behandling af CNS-lidelser | |
| DK2040713T3 (da) | Galdesyrederivater som fxr-ligander til forebyggelsen eller behandlingen af fxr-medierede sygdomme eller tilstande | |
| DK2796469T3 (da) | Hidtil ukendte sammensætninger og fremgangsmåder til behandling af IgE-medierede forstyrrelser | |
| DK1830843T3 (da) | Indolidon-derivater til behandling eller forebyggelse af fibrotiske sygdomme | |
| CL2007002930A1 (es) | Un compuesto 4-[4-({[4-cloro-3-(trifluorometil)fenil]carbamoil}amino)-3-fluorofenoxi]-n-metilpiridin-2-carboxamida monohidratado; proceso de preparacion; composicion y combinacion farmaceutica; y uso para el tratamiento de trastornos hiperproliferati | |
| ZA201101891B (en) | The salts of n-[4-(1-cyanocyclopentyl)phenyl]-2-(4-pyridyl methyl)amino-3-pyridinecarboxamide | |
| DK1830850T3 (da) | Quinolin-derivater til behandling af latent tuberkulose | |
| UA100364C2 (xx) | Сукцинат біфеніл-2-ілкарбамінової кислоти 1-$2-(2-хлор-4-{$(r)-2-гідрокси-2-(8-гідроксі-2-оксо-1,2-дигідрохінолін-5-іл)етиламіно]метил]}-5-метоксифенілкарбамоїл)етил]піперидин-4-іл-естеру та його застосування для лікування легеневих розладів | |
| DK1817282T3 (da) | Til behandling af respiratoriske sygdomme egnede phenoxy derivater | |
| DK1948176T3 (da) | Diarylurinstoffer til behandling af pulmonær hypertension | |
| DK1838697T3 (da) | Fremgangsmåder til at fremstille 4-(phenoxy-5-methyl-pyrimidin-4-yloxy)-piperidin-1-carboxylsyre-derivater og relaterede forbindelser | |
| DK1599452T3 (da) | 3- (2-phenyloxazol- 4-ylmethoxy) - cyclohexylmethoxyeddikesyrederivater og beslægtede forbindelser som PPAR modulatorer til behandling af type 2 diabetes og atherosklerosw |